Intercell Receives CHMP Positive Opinion for the Pediatric Indication of IXIARO®

News   Dec 20, 2012

 
Intercell Receives CHMP Positive Opinion for the Pediatric Indication of IXIARO®
 
 
 

RELATED ARTICLES

Immune Cells Form Clots in Tumors Aiding Lung Cancer's Spread

News

Researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.

READ MORE

Strong Immune Response in Diseased Corals Potential Trade-Off

News

Researchers have found a correlation between a strong immune response in diseased corals and a lower expression of genes associated with growth and reproduction.

READ MORE

Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug Development

News

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy